Clinical trial
A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
NCT03866109 · Genenta Science, Industry · Active, not recruiting
Key facts
| NCT number | NCT03866109 |
|---|---|
| Title | A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT |
| Official title | A Phase I/IIa Dose Escalation Study Evaluating the Safety and Efficacy of Autologous CD34+-Enriched HSPCs Genetically Modified With Human Interferon-α2 in Patients With Glioblastoma Multiforme and Unmethylated MGMT Gene Promoter |
| Acronym | TEM-GBM |
| Lead sponsor | Genenta Science, Industry |
| Status | Active, not recruiting |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme |
| Intervention type | Drug |
| Interventions | Temferon |
| Enrollment | 27 |
| Start date | Mar 5, 2019 |
| Primary completion | Jun 30, 2026 |
| Completion | Jun 30, 2026 |
| First posted | Mar 7, 2019 |
| Last update posted | Feb 9, 2026 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: